MONTREAL, July 08, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, has signed a licensing agreement with an International pharmaceutical manufacturer whereby Valeo has been granted the exclusive right to register, distribute and market a low molecular weight heparin ("LMWH") biosimilar in Canada.
LMWH is an injectable anticoagulant drug used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.Total Canadian sales of LMWHs were in excess of $200M in 2018 and there are currently no LMWH biosimilars which have received Health Canada approval.
"This licensing agreement provides us with the opportunity to be the first LMWH biosimilar to enter the market" commented Steve Saviuk, CEO of Valeo. "The addition of this drug product furthers our growing Hospital Specialty portfolio and the market opportunity that it represents can be transformational for our Company."
About Valeo Pharma
Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on Neurodegenerative Diseases, Oncology, Women's Health and Hospital Specialty Products, Valeo Pharma has a growing portfolio of innovative products and the full infrastructure to properly manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all capabilities internally to register and market health care solutions for Canadian patients. For more information, please visit www.valeopharma.com and follow us on Linkedin and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Valeo Pharma inc.
For further information: Valeo Pharma: Steve Saviuk - President and CEO, Phone : +1 514 693-8830, Email : [email protected]; Frederic Dumais - Director Communications and Investor Relations, Phone: 514-782-8803, Email: [email protected]